Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Müge Çevik, Lindsay C Thompson, Caryn M. Upton, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 1003-1014
Open Access | Times Cited: 16

Showing 16 citing articles:

Tuberculosis
Anete Trajman, Jonathon R. Campbell, Tenzin Kunor, et al.
The Lancet (2025) Vol. 405, Iss. 10481, pp. 850-866
Closed Access | Times Cited: 4
Advancing the chemotherapy of tuberculous meningitis: a consensus view
Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 5
stormTB: a web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments
Roberto Visintainer, Anna Fochesato, Daniele Boaretti, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Recent advancements in tuberculosis (TB) treatment regimens
Shyamala Ravikoti, Vikas Bhatia, S.K. Mohanasundari
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 2, pp. 521-525
Open Access
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
Christoph Lange, Graham Bothamley, Gunar Günther, et al.
Pathogens and Immunity (2025) Vol. 10, Iss. 2, pp. 1-45
Open Access
Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden
Christian Michael, Maral Budak, Pauline Maiello, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Immune dysregulation of diabetes in tuberculosis
Pei Min Thong, Yi Hao Wong, Hardy Kornfeld, et al.
Seminars in Immunology (2025) Vol. 78, pp. 101959-101959
Open Access
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis
Heena Soni, Sandeep Tyagi, Kishor Mane, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial
Nicholas I. Paton, C S G Cousins, Intan Permata Sari, et al.
The Lancet Infectious Diseases (2025)
Open Access
Predictable excess hepatotoxicity in the SimpliciTB trial
William J. Burman, C. Robert Horsburgh, James C. Johnston
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 1
Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Oliver Komm, Sandeep Tyagi, Andrew Garcia, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 69, Iss. 1
Open Access | Times Cited: 1
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis
Guofang Deng, Liang Fu
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 940-941
Closed Access
Predictable excess hepatotoxicity in the SimpliciTB trial – Authors’ reply
Müge Çevik, Maria Beumont, Eugene Sun, et al.
The Lancet Infectious Diseases (2024)
Closed Access
Saliva-based point-of-care assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer
Ricky Hao Chen, Thi Anh Nguyen, Hannah Yejin Kim, et al.
Journal of Antimicrobial Chemotherapy (2024)
Open Access
Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment
Nacer Lounis, Tom J.G. Gevers, Cristina Villellas, et al.
Deleted Journal (2024) Vol. 1, Iss. 11, pp. 525-527
Open Access
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
Denise Rossato Silva, Flávia Fonseca Fernandes, Juliana Carvalho Ferreira, et al.
Jornal Brasileiro de Pneumologia (2024), pp. e20240295-e20240295
Open Access
Combating drug-resistant tuberculosis in South Africa: strategies, challenges, and progress
William Brumskine
South African General Practitioner (2024) Vol. 5, Iss. 4, pp. 159-164
Open Access
Page 1

Scroll to top